John Eikelboom, MD, of McMaster University discusses the 3 arms of the COMPASS trial and explains the need for it to end earlier than anticipated.
John Eikelboom, MD, of McMaster University discusses the 3 arms of the COMPASS trial and explains the need for it to end earlier than anticipated.
Transcript (slightly modified)
What were the basic findings of the COMPASS trial and why was it stopped early?
The COMPASS trial was a 3-arm study and it tested the combination of rivaroxaban—about 2.5 mg twice a day—and aspirin; rivaroxaban alone; and aspirin alone. The winning arm in this study was the combination, which was superior to aspirin. The Data Safety Monitoring Board stopped the trial early because they found that the difference in treatment effects and the event rates were so different at the interim analysis, that it exceeded the stopping rule.
The results to summarize: the combination, compared with aspirin, reduced the primary outcome of cardiovascular death, stroke, or myocardial infarction by 24% with a consistent effect on the components of that outcome. It also reduced the outcome of mortality—so, an 18% reduction in mortality. There was a price to pay, and the price to pay was an increase in bleeding and the hazard ratio was 1.7, so there was clearly an increase in bleeding. But, reassuringly, there was no excess of the most severe bleeds.
When we look at the net benefit, the ultimate measure of net benefit is actually mortality and there was a reduction in mortality, as I’ve mentioned. There was also a reduction in a pre-specified net benefit analysis that included the primary outcome and the severe bleeds.
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Study Highlights BMP7 as a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More